FDA Approval of VIZIMPRO® (dacomitinib) tablets

Pfizer Oncology is proud to announce the FDA approval of VIZIMPRO® (dacomitinib) tablets on September 27^th, 2018. The following information is for State Society review:

• See the full Prescribing Information
• Read the Press Release

If you should have any questions, please contact me at your earliest convenience. If you prefer not to be sent these kinds of emails, please let me know and I will not send these to you in the future.